Divi's Laboratories shares
Divi’s Laboratories is one of India’s leading Contract Research, Development & Manufacturing (CRDMO) companies. Analysts expect increasing outsourcing by global pharmaceutical companies to support long-term revenue growth.
The company remains one of the world’s largest manufacturers of Active Pharmaceutical Ingredients (APIs), supplying regulated markets such as the US and Europe.
Many global pharmaceutical companies continue to diversify manufacturing away from China, positioning Divi’s as a key beneficiary over the coming years.
These qualities make Divi’s one of the strongest pharmaceutical businesses in India.
Recent quarterly results showed robust profit growth driven by custom synthesis and API demand, reinforcing confidence in long-term earnings.
Divi’s often trades at a higher valuation than many pharma peers, leaving less room for error if growth slows.
Generic drug pricing pressure in the US continues to affect the pharmaceutical sector and could weigh on margins.
Revenue from a limited number of large global pharmaceutical customers means delays or order changes can affect quarterly performance.
As with all pharmaceutical manufacturers, inspections by regulators such as the US FDA remain an ongoing operational risk.
Some analysts believe much of Divi’s quality is already reflected in its share price, leading to a more balanced near-term outlook.
| Brokerage | Rating | Target Price |
|---|---|---|
| Goldman Sachs | Buy | ₹8,035 |
| JPMorgan | Buy | ₹7,400 |
| Macquarie | Buy | ₹7,500 |
| HSBC | Hold | ₹6,900 |
| ICICI Securities | Sell | ₹6,150 |
| Year | Conservative | Bullish |
|---|---|---|
| 2027 | ₹7,400 | ₹8,300 |
| 2028 | ₹8,200 | ₹9,700 |
| 2029 | ₹9,000 | ₹11,200 |
| 2030 | ₹9,800 | ₹12,800 |
| 2031 | ₹10,500 | ₹14,000 |
If Divi’s successfully expands its CDMO business, captures a larger share of GLP-1 manufacturing, maintains operating margins above 30%, and compounds earnings at more than 20% annually, the stock could potentially reach ₹15,000–₹18,000 by 2031. This represents an optimistic scenario rather than a base-case forecast.
ABB India surged over 8% today because investors focused on its long-term growth story rather…
The recent Q1 FY27 earnings release from ICICI Lombard General Insurance Co. Ltd. (NSE: ICICIGI)…
[et_pb_section][et_pb_row][et_pb_column type="4_4"][et_pb_text] Tata Power – Building India's Energy Future Tata Power Ltd. is one of…
The 9:00 AM–9:08 AM pre-open session can provide useful clues about market sentiment, but it…
🟢 Bullish Analyst Opinions 1. India's Largest Private Thermal Power Producer Adani Power continues to…
Overall Analyst Consensus Consensus Rating: Buy Analysts Covering: 31 Buy: 22 Hold: 8 Sell: 1…